Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, January 1998, p. 170-172, Vol. 42, No. 1
Rega Institute for Medical Research,
Katholieke Universiteit Leuven, B-3000 Leuven, Belgium
Received 27 May 1997/Returned for modification 16 September
1997/Accepted 20 October 1997
We have evaluated the susceptibility of the murine gamma
herpesvirus 68 (MHV-68) to a variety of antiviral agents. The acyclic nucleoside phosphonate analogs cidofovir
[(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine], (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)adenine (HPMPA),
and adefovir [9-(2-phosphonylmethoxyethyl)adenine] efficiently
inhibited the replication of the virus in Vero cells (50% effective
concentrations [EC50s], 0.008, 0.06, and 2.2 µg/ml,
respectively). Acyclovir, ganciclovir, and brivudin
[(E)-5-(2-bromovinyl)-2'-deoxyuridine] had equipotent
activities (EC50s, 1.5 to 8 µg/ml), whereas foscarnet and
penciclovir were less effective (EC50s, 23 and Murine gamma herpesvirus 68 (MHV-68)
is a murine gamma herpes virus closely related to Epstein-Barr
virus (EBV), human herpesvirus 8, and herpesvirus saimiri (HVS)
(5, 16). Like EBV and HVS, MHV-68 may induce
lymphoproliferative diseases (20). Little is known about the
susceptibility of MHV-68 to antiviral agents. Sunil-Chandra et al.
(18, 19) have evaluated the anti-MHV-68 activity of
acyclovir (ACV), but no comparative study of the activities of
different antiviral agents against MHV-68 has been reported so far. To
investigate whether MHV-68 may serve as a surrogate for EBV in the
development of antiviral strategies, we evaluated the sensitivity of
MHV-68 to a variety of antiherpesvirus agents with known anti-EBV
activity. Furthermore, knowledge about the susceptibility of MHV-68 to
antiviral drugs may provide deeper insight into the mode of replication
of this virus.
MHV-68 clone G2.4 was kindly provided by A. A. Nash
(Edinburgh, United Kingdom) and was propagated in Vero B cells.
Confluent cultures of Vero B cells grown in 96-well microtiter plates
were infected with MHV-68 at a multiplicity of infection that yields a
100% cytopathic effect at 7 days postinfection (p.i.). After a 2-h
adsorption period, the virus was removed and serial dilutions of the
different compounds were added. The cytopathic effect was recorded
microscopically at 7 days p.i. The sources of the compounds were as
reported earlier (2, 14). The cytostatic effects of the
compounds were determined on growing Vero cell cultures. Cells were
seeded at a density of 4,000 cells per well and were allowed to stick
to the plates for at least 6 h. Then, serial dilutions of the
compounds in 10% fetal calf serum were added. After 3 days the cells
were trypsinized and the cell numbers were determined with a
Coulter counter.
The anti-MHV-68 activities of the selected compounds are presented in
Table 1. ACV and ganciclovir (GCV) had
about equipotent anti-MHV-68 activities, whereas penciclovir (PCV) was
only a weak inhibitor of MHV-68 replication. Brivudin
[(E)-5-(2-bromovinyl)-2'-deoxyuridine] (BVDU), a molecule
that, like ACV, PCV, and GCV, depends on a virus-encoded thymidine
kinase (TK) for activation, inhibited MHV-68 replication in the same
concentration range as ACV and GCV. The antiviral activity of cidofovir
[(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine; HPMPC] and
(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)adenine (HPMPA),
two molecules that do not depend on the viral TK, appeared to be very
pronounced: they exhibited 50% effective concentrations (EC50s) of 0.008 to 0.06 µg/ml; this is 50- to 100-fold
lower than the EC50s of ACV and GCV. In contrast, the
EC50s of cidofovir and HPMPA for inhibition of herpes
simplex virus type 1 (HSV-1) and HSV-2 replication in Vero cells are
comparable to those of ACV and GCV (13a). Thus, the
active (diphosphorylated) metabolites of HPMPC and HPMPA (i.e.,
HPMPCpp and HPMPApp) may be expected to be potent inhibitors of the
MHV-68 DNA polymerization process. Another acyclic nucleoside
phosphonate, adefovir [9-(2-phosphonylmethoxyethyl)adenine] (PMEA), which has potent antiretrovirus and antiherpesvirus
activities (10), also efficiently inhibited the
replication of MHV-68 (EC50, 2.2 ± 0.5 µg/ml). This EC50 is comparable to the EC50s
of ACV and GCV and is 10-fold lower than the EC50 of
foscarnet.
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
In Vitro and In Vivo Inhibition of Murine Gamma
Herpesvirus 68 Replication by Selected Antiviral Agents
ABSTRACT
Top
Abstract
Text
References
30
µg/ml, respectively). The novel N-7-substituted nucleoside analog
S2242 [7-(1,3-dihydroxy-2-propoxymethyl)purine] inhibited MHV-68
replication by 50% at 0.2 µg/ml. The susceptibilities of MHV-68 and
Epstein-Barr virus (EBV) to cidofovir, HPMPA, adefovir, and acyclovir
were found to be comparable. However, for penciclovir, ganciclovir, brivudin, and S2242, major differences in the sensitivity of MHV-68 and
EBV were observed, suggesting that MHV-68 is not always an optimal
surrogate for the study of antiviral strategies for EBV. When evaluated
with a model for lethal MHV-68 infections in mice with severe combined
immunodeficiency, cidofovir proved to be very efficient in protecting
against virus-induced mortality (100% survival at 50 days
postinfection), whereas acyclovir, brivudin, and adefovir had little or
no effect.
TEXT
Top
Abstract
Text
References
TABLE 1.
In vitro activities of selected antiviral agents
against MHV-68 replicationa
We next evaluated the effects of cidofovir, adefovir, brivudin, and ACV in an animal model of lethal MHV-68 infection (Table 2). To mimic the situation in the immunodeficient host, antiviral efficacy was studied in mice with severe combined immunodeficiency (SCID mice). In immunocompetent mice, suboptimal doses of the antiviral drugs may be sufficient to protect against mortality in the early stages of infection; the mice may mount an efficient immune response and finally survive the infection. In SCID mice, chemotherapeutic means may be the only means of suppressing the infection. In the present study SCID mice were infected intraperitoneally with a dose of MHV-68 that caused 100% mortality in a time span of 2 weeks. At that time, virus was recovered from the lungs, liver, kidney, and spleen (data not shown). Animals were treated subcutaneously for 5 consecutive days a week (until the end of the experiment), starting at 2 h p.i., at a dosage of 25 mg of the different drugs per kg of body weight per day. Neither ACV nor brivudin had any effect on survival in this model, whereas adefovir had some minor effect on the delay in virus-induced mortality. Also, in the study of Sunil-Chandra et al. (19) in which the titers in organs were used as the endpoint for the antiviral activity of ACV, the compound did not cause more than a 10-fold reduction in virus titer. In contrast, we found that cidofovir caused a marked and sustained protection against virus-associated morbidity and mortality. All cidofovir-treated animals survived the infection for more than 50 days p.i. (i.e., for more than 3 weeks after administration of the last dose).
|
An interesting feature of cidofovir is its prolonged antiviral effect, which lasts even long after the extracellular compound has been removed (11). The long intracellular half-life of the drug metabolites is responsible for this effect (1). The long-lasting antiviral action of cidofovir has also been described in the clinical setting (15). Even after the levels of cidofovir in plasma have fallen well below the EC50 for the inhibition of viral replication, the intracellular levels of the drug metabolites are still sufficiently high to inhibit viral replication. This feature of cidofovir may be an important determinant of its marked activity in the MHV-68 infection model in mice. The lack of protection afforded by ACV and brivudin in this model may result from (i) a less efficient intracellular storage of drug metabolites and/or (ii) a lower in vitro susceptibility of the virus to these antiviral agents.
In another experiment, MHV-68-infected SCID mice were treated for 5 consecutive weeks (5 days a week) with 25 mg of cidofovir (subcutaneously) per kg per day. Control animals (n = 4) died at 15.7 ± 0.5 days p.i. Cidofovir-treated animals remained healthy for 3 to 4 weeks after therapy was stopped. No virus could be recovered from their organs following cidofovir treatment (as evaluated by titration of homogenized organs [brain, lung, kidney, spleen, and liver] during the 3rd week of treatment). About 1 month after administration of the last dose, signs of MHV-68-associated morbidity started to appear. The animals (n = 4) were sacrificed at the time that they were clearly ill (82 ± 5.5 days p.i.). Substantial levels of MHV-68 were detected in the organs of these mice at that time (data not shown). Thus, (i) since viral replication is suppressed during cidofovir treatment but (ii) the animals become ill and ultimately die from the infection about 50 days after the last cidofovir dose has been given, the virus must be reactivated from an inactive state. It has been suggested that MHV-68 persists in latent form in B cells (17). However, since SCID mice do not harbor B cells (4), one must conclude that MHV-68 can also hide in other cells of the organism. Further investigations are needed to determine this site(s) of latency.
MHV-68 has been suggested as a possible surrogate for the study of the pathogenesis and therapy of EBV infections (18, 19). We therefore compared the inhibitory effect of the compounds evaluated in this study with the values for the inhibition of EBV replication reported in the literature (Table 1). The susceptibilities of MHV-68 and EBV to the acyclic nucleoside phosphonates cidofovir, HPMPA, and adefovir, as well as ACV, appeared to be more or less comparable. However, MHV-68 proved to be much less sensitive than EBV to several other compounds, such as GCV, PCV, and S2242 [7-(1,3-dihydroxy-2-propoxymethyl)purine]. This may be related to differences in the metabolism of the compounds in lymphoid cells (in which the anti-EBV assays are performed) compared to that in Vero cells (in which the anti-MHV-68 assays are performed). In fact, we found that S2242 is much more efficiently metabolized in lymphoid cells than in Vero cells (12, 13). In addition, or alternatively, the antiviral agents or their intracellular metabolites may interfere with different potencies with the DNA polymerases of EBV and MHV-68. In conclusion, the study of the susceptibility of MHV-68 to antiviral drugs may provide useful information on the drug sensitivity patterns of gamma herpesviruses. An in vitro infection model in B lymphocytes would eliminate cell line-dependent variations in the intracellular metabolism of the antiviral agents and allow for a direct comparison of the anti-MHV-68 and anti-EBV activities of an antiviral agent in the same cell type.
| |
ACKNOWLEDGMENTS |
|---|
This study was supported by grant 3.0180.95 from the Belgian "Fonds voor Geneeskundig Wetenschappelijk Onderzoek (FGWO)."
We thank A. A. Nash (Edinburgh, United Kingdom) for kindly providing MHV-68. We thank Willy Zeegers and Miette Stuyck for expert assistance with the experiments and Christiane Callebaut and Dominique Brabants for excellent editorial assistance.
Johan Neyts is a postdoctoral research assistant from the "Fonds voor Wetenschappelijk Onderzoek-Vlaanderen (FWO)."
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium. Phone: 32 16 337353. Fax: 32 16 337340. E-mail: Johan.Neyts{at}rega.kuleuven.ac.be.
| |
REFERENCES |
|---|
|
Top
Abstract
Text
References
|
|---|
| 1. | Aduma, P. P., M. C. Connelly, R. V. Srinivas, and A. Fridland. 1995. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates. Mol. Pharmacol. 47:816-822[Abstract]. |
| 2. | Andrei, G., R. Snoeck, D. Schols, P. Goubau, J. Desmyter, and E. De Clercq. 1991. Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus. Eur. J. Clin. Microbiol. Infect. Dis. 10:1026-1033[Medline]. |
| 3. | Bacon, T. H., and M. R. Boyd. 1995. Activity of penciclovir against Epstein-Barr virus. Antimicrob. Agents Chemother. 39:1599-1602[Abstract]. |
| 4. | Bosma, G. C., R. P. Custer, and M. J. Bosma. 1983. A severe combined immunodeficiency mutation in the mouse. Nature 301:527-530[Medline]. |
| 5. |
Efstathiou, S.,
Y. M. Ho,
S. Hall,
C. J. Styles,
S. D. Scott, and U. A. Gompels.
1990.
Murine herpesvirus 68 is genetically related to the gammaherpesviruses Epstein-Barr virus and herpesvirus saimiri.
J. Gen. Virol.
71:1365-1372 |
| 6. |
Lin, J. C.,
M. C. Smith, and J. S. Pagano.
1984.
Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus.
J. Virol.
50:50-55 |
| 7. |
Lin, J. C.,
E. De Clercq, and J. S. Pagano.
1987.
Novel acyclic adenosine analogues inhibit Epstein-Barr virus replication.
Antimicrob. Agents Chemother.
31:1431-1433 |
| 8. |
Lin, J.-C.,
E. De Clercq, and J. S. Pagano.
1991.
Inhibitory effects of acyclic nucleoside phosphonate analogs, including (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, on Epstein-Barr virus replication.
Antimicrob. Agents Chemother.
35:2440-2443 |
| 9. | Meerbach, A., J. Neyts, A. Holý, P. Wutzler, and E. De Clercq. Inhibitory effect of novel nucleoside and nucleotide analogues on Epstein-Barr virus replication. Submitted for publication. |
| 10. | Naesens, L., R. Snoeck, A. Andrei, J. Balzarini, J. Neyts, and E. De Clercq. 1997. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antivir. Chem. Chemother. 8:1-23. |
| 11. | Neyts, J., R. Snoeck, J. Balzarini, and E. De Clercq. 1991. Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro. Antivir. Res. 16:41-52[Medline]. |
| 12. |
Neyts, J.,
G. Andrei,
R. Snoeck,
G. Jähne,
I. Winkler,
M. Helsberg,
J. Balzarini, and E. De Clercq.
1994.
The N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine is a potent and selective inhibitor of herpesvirus replication.
Antimicrob. Agents Chemother.
38:2710-2716 |
| 13. | Neyts, J., J. Balzarini, G. Andrei, Z. Chaoyong, R. Snoeck, A. Zimmerman, T. Mertens, A. Karlsson, and E. De Clercq. Intracellular metabolism of the N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxymethyl)]purine, a potent inhibitor of herpesvirus replication. Mol. Pharmacol., in press. |
| 13a. | Neyts, J., and E. De Clercq. Unpublished data. |
| 14. | Reymen, D., L. Naesens, J. Balzarini, A. Holý, H. Dvoráková, and E. De Clercq. 1995. Antiviral activity of selected acyclic nucleoside analogues against human herpesvirus 6. Antivir. Res. 28:343-357[Medline]. |
| 15. | Snoeck, R., G. Andrei, M. Gérard, A. Silverman, A. Hedderman, J. Balzarini, C. Sadzot-Delvaux, G. Tricot, N. Clumeck, and E. De Clercq. 1994. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Clin. Infect. Dis. 18:943-944. |
| 16. |
Sunil-Chandra, N. P.,
S. Efstathiou,
J. Arno, and A. A. Nash.
1992.
Virological and pathological features of mice infected with murine gammaherpesvirus 68.
J. Gen. Virol.
73:2347-2356 |
| 17. | Sunil-Chandra, N. P., S. Efstathiou, and A. A. Nash. 1993. Interactions of murine gammaherpesvirus 68 with B and T cell lines. Virology 193:825-833[Medline]. |
| 18. | Sunil-Chandra, N. P., A. G. C. Barnes, and A. A. Nash. 1994. A novel murine model for studying antiviral compounds against EBV. Int. Antivir. News 2:102-104. |
| 19. | Sunil-Chandra, N. P., S. Efstathiou, and A. A. Nash. 1994. The effect of acyclovir on the acute and latent murine gammaherpesvirus-68 infection of mice. Antivir. Chem. Chemother. 5:290-296. |
| 20. | Usherwood, E. J., J. P. Stewart, and A. A. Nash. 1996. Characterization of tumor cell lines derived from murine gammaherpesvirus-68-infected mice. J. Virol. 70:6516-6518[Abstract]. |
Antimicrobial Agents and Chemotherapy, January 1998, p. 170-172, Vol. 42, No. 1
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Forrest, J. C., Paden, C. R., Allen, R. D. III, Collins, J., Speck, S. H.
(2007). ORF73-Null Murine Gammaherpesvirus 68 Reveals Roles for mLANA and p53 in Virus Replication. J. Virol.
81: 11957-11971
[Abstract] [Full Text] -
Flano, E., Jia, Q., Moore, J., Woodland, D. L., Sun, R., Blackman, M. A.
(2005). Early Establishment of {gamma}-Herpesvirus Latency: Implications for Immune Control. J. Immunol.
174: 4972-4978
[Abstract] [Full Text] -
Yarilin, D. A., Valiando, J., Posnett, D. N.
(2004). A Mouse Herpesvirus Induces Relapse of Experimental Autoimmune Arthritis by Infection of the Inflammatory Target Tissue. J. Immunol.
173: 5238-5246
[Abstract] [Full Text] -
Symensma, T. L., Martinez-Guzman, D., Jia, Q., Bortz, E., Wu, T.-T., Rudra-Ganguly, N., Cole, S., Herschman, H., Sun, R.
(2003). COX-2 Induction during Murine Gammaherpesvirus 68 Infection Leads to Enhancement of Viral Gene Expression. J. Virol.
77: 12753-12763
[Abstract] [Full Text] -
De Clercq, E.
(2003). Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections. Clin. Microbiol. Rev.
16: 569-596
[Abstract] [Full Text] -
Coleman, H. M., Lima, B. d., Morton, V., Stevenson, P. G.
(2003). Murine Gammaherpesvirus 68 Lacking Thymidine Kinase Shows Severe Attenuation of Lytic Cycle Replication In Vivo but Still Establishes Latency. J. Virol.
77: 2410-2417
[Abstract] [Full Text] -
Gangappa, S., Kapadia, S. B., Speck, S. H., Virgin, H. W. IV
(2002). Antibody to a Lytic Cycle Viral Protein Decreases Gammaherpesvirus Latency in B-Cell-Deficient Mice. J. Virol.
76: 11460-11468
[Abstract] [Full Text] -
Dal Canto, A. J., Virgin, H. W. IV, Speck, S. H.
(2000). Ongoing Viral Replication Is Required for Gammaherpesvirus 68-Induced Vascular Damage. J. Virol.
74: 11304-11310
[Abstract] [Full Text]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»